Key Highlights

  • Second-quarter coverage describes record net bookings and lower cancellations.
  • Management raised 2026 guidance, projecting double-digit revenue and EBITDA growth.
  • Trailing revenue is $2.78 billion with net income of $491.5 million.
  • Third-quarter results are due October 21 after the market close.

Medpace Holdings, Inc. (NASDAQ:MEDP) has a market value of about $17.31 billion and reports third-quarter 2026 results on October 21 after the market close. The angle is company-specific: the interaction between record bookings, cancellation rates and a year of volatility. Several analysts have recently adjusted price targets, which may make the upcoming report a focal point for sentiment.

Latest Company Context

Medpace reported second-quarter 2026 results on July 23, 2026. Coverage of the earnings call describes record net bookings, lower cancellations and raised 2026 guidance, with management projecting double-digit revenue and EBITDA growth; these are management guidance, not outcomes. For full-year 2025, revenue was $2.53 billion, up about 20%, and earnings were $451.1 million. On a trailing twelve-month basis revenue is $2.78 billion and net income $491.5 million. Earlier in 2026, securities class action notices were published in May concerning cancellation rates; these are allegations by plaintiff law firms, not findings. Recent analyst moves include Mizuho lifting its target to $700 from $665, Barclays to $625 from $600, and UBS resuming coverage with a Neutral rating and $673 target.

Key Business Drivers

Medpace provides outsourced clinical development services, largely to small and mid-sized biotechnology and pharmaceutical sponsors. Its revenue depends on backlog conversion, which in turn depends on net new bookings and cancellations. Biotech funding conditions are therefore a key external driver: stronger capital markets may support new study starts, while tighter funding could lead sponsors to delay or cancel programmes. Because cancellations were the focus of earlier investor concern, the trend reported in Q2 as lower is closely tracked. Margin trends, staffing and pass-through revenue are additional variables. Analyst consensus is described as Hold with a 12-month average price target of $595.92.

What Investors Should Watch

The immediate catalyst is the October 21 third-quarter report after the close. Investors may watch net bookings, the book-to-bill ratio, backlog growth and the cancellation rate against the Q2 trend. Any change to the full-year 2026 outlook, including the double-digit revenue and EBITDA growth framework, could influence sentiment, as may commentary on biotech funding and 2027 expectations. Other items include margin performance, share repurchase activity, and any developments in the class action matters. Subsequent analyst target revisions may also follow results.

Bookings and Cancellations Set the Terms for the Next Report

Medpace heads into its Q3 report with improved booking and cancellation trends reported last quarter and a legal overhang from earlier this year. The class action notices are allegations by plaintiff law firms, not findings.